The FDA has authorized the emergency use of Paxlovid, an investigational medicine, for the treatment of mild-to-moderate COVID-19 in adults and children 12 years of age and older who are at high risk for progression to severe COVID-19, including hospitalization or death.
The drug is investigational because it is still being studied. There is limited information about the safety and effectiveness of using Paxlovid to treat people with mild-to-moderate COVID?19.
A new report now addresses the claim that the new drug could be causing a Covid rebound, actually increasing cases. Is this true?
The confusion stems over the number of people who have taken the drug who within a week have symptoms return and test positive a second time later for COVID. Is this due to the side effects of the drug or the condition of those taking it with severe cases? The question is still being studied, but the number of cases are concerning enough to lead to heightened attention over the drug potentially making the virus worse in the long run.
It’s not the news Americans want to hear as the focus on vaccines and other methods did not really stop the virus as promised. Instead, many vaccinated Americans tested positive for COVID, especially the Omicron variant. The antiviral medicines were supposed to be the next answer, but it may not be ideal either, depending on the outcome of longer-term research.
Check out the video for the full details now about this surprising development.